John Langridge
10Patents
8h-index
9Co-inventors
65Inventor score
Filing activity: May 24, 1985 → Dec 4, 2007
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4717569A | Unit dosage form of sparingly soluble medicaments | Human Necessities | 56 | Expired |
| US5209933A | Long acting calcium channel blocker composition | Human Necessities | 20 | Expired |
| US4806361A | Medicaments in sustained release unit dose form | Human Necessities | 17 | Expired |
| US6303607A | Method for administering a sustained release ranolanolazine formulation | Human Necessities | 14 | Expired |
| US6525057B2 | Sustained release ranolazine formulations | Human Necessities | 12 | Expired |
| US6369062B1 | Sustained release ranolazine formulations | Human Necessities | 11 | Expired |
| US6620814B2 | Sustained release ranolazine formulations | Human Necessities | 11 | Expired |
| US6617328B2 | Sustained release ranolazine formulations | Human Necessities | 9 | Expired |
| US6503911B2 | Sustained release ranolazine formulations | Human Necessities | 7 | Expired |
| US8865778B2 | Extended release excipient and its use | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.